Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05XCV
|
||||
Former ID |
DNC009723
|
||||
Drug Name |
Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C36H40N6O5
|
||||
Canonical SMILES |
CC(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CNC4=CC=C<br />C=C43)C(=O)NC(CC5=CC=CC=C5)C(=O)N
|
||||
InChI |
1S/C36H40N6O5/c1-23(43)42-18-10-17-32(42)36(47)41-30(20-25-13-6-3-7-14-25)34(45)40-31(21-26-22-38-28-16-9-8-15-27(26)28)35(46)39-29(33(37)44)19-24-11-4-2-5-12-24/h2-9,11-16,22,29-32,38H,10,17-21H2,1H3,(H2,37,44)(H,39,46)(H,40,45)(H,41,47)/t29-,30-,31+,32+/m0/s1
|
||||
InChIKey |
WEBVKDVBAOYUMD-GASGPIRDSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Enkephalin release | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | TCR Signaling Pathway | ||||
GPCRs, Class A Rhodopsin-like | |||||
Peptide GPCRs | |||||
Opioid Signalling | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.